{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-008631","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.768997+00:00","generated_at":"2026-05-16T11:08:15.940027+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Heron Therapeutics preliminary Q4 2025 net revenue $40.5M; full-year $154.9M","bullets":["Q4 2025 net revenue approximately $40.5M, driven by Acute Care franchise momentum.","Full-year 2025 net revenue approximately $154.9M (preliminary, unaudited).","ZYNRELEF net revenue $12.5M in Q4, up ~35% vs Q3 2025, largest product growth.","APONVIE net revenue $3.8M, CINVANTI $22.9M, SUSTOL $1.3M in Q4 2025.","CEO Craig Collard cites continued progress across all aspects of business."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-008631","json":"https://secwatch.observer/filing/0001193125-26-008631.json","markdown":"https://secwatch.observer/filing/0001193125-26-008631.md","text":"https://secwatch.observer/filing/0001193125-26-008631.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000119312526008631/0001193125-26-008631-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000119312526008631/hrtx-20260109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:08:15.940027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}